Aimmune Investors' $27.5M Deal In Nestle Suit Gets Final OK
Investors in biopharmaceutical company Aimmune Therapeutics Inc. have gotten final approval for their $27.5 million deal resolving claims the company was falsely undervalued before its merger with Nestlé Health Science SA....To view the full article, register now.
Already a subscriber? Click here to view full article